Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Irinotecan and capecitabine are approved to be the effective drugs for the advanced colorectal cancer patients. However, the combination of these two drugs are not regularly recommended due to the severe diarrhea as the most common adverse event.This study was designed to explore whether the single-week regimen of irinotecan plus capecitabine improves efficacy and does not increase the toxicity in advanced colorectal cancer patients in China.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
Histologically confirmed colorectal cancer
Age 18-70 years old
Advanced colorectal cancer patients, first-line or second-line treatment, the adjuvant treatment including the oxaliplatin or/and 5FU should be finished six months before
Have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
ECOG 0-1
Life expectancy of more than 3 months.
Normal laboratory values: hemoglobin \> 90g/dl, neutrophils \> 1.5×10\^9/L, platelets \> 100×10\^9/L, serum creatinine \< 1.5×upper limit of normal (ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN, AKP \< 4×ULN
You may not be if
Pregnant or lactating patients
Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety
Active or uncontrolled infection
Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure
Patients could not swallow the tablets
Concomitant with brain metastases
Clareo Health | Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer
